CDIO, CDIOW · CIK 0001870144 · operating
Based in Chicago, Cardio Diagnostics Holdings develops and commercializes epigenetics-based diagnostic tests for cardiovascular disease risk assessment and detection. The company's primary clinical offerings include Epi+Gen CHD, a blood test that assesses three-year risk of symptomatic coronary heart disease events such as heart attacks, and PrecisionCHD, an integrated epigenetic-genetic blood test designed to detect coronary heart disease. The company also operates Actionable Clinical Intelligence, a platform that delivers epigenetic and genetic insights to clinicians for chronic disease management.
Beyond its clinical diagnostics, Cardio Diagnostics offers CardioInnovate360, a research-use-only solution supporting discovery and development of cardiovascular biopharmaceuticals, and HeartRisk, a software-as-a-service platform providing cardiovascular disease risk intelligence. The company serves multiple customer segments including telemedicine providers, provider organizations such as concierge practices and longevity clinics, and employer organizations.
The company operates at a small scale with 13 full-time employees and is listed on Nasdaq. Cardio Diagnostics was incorporated in Delaware and founded in 2017.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.31 | $-0.31 | +53.0% | |
| 2023 | $-0.66 | $-0.66 | +56.3% | |
| 2022 | $-1.51 | $-1.51 | — | |
| 2021 | — | — | — |